Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03414229 | A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | PHASE2 | ACTIVE NOT_RECRUITING | 30 | — | — | Jan 23, 2018 | Jan 1, 2027 | Apr 23, 2026 | 1 | United States |
by RECIST 1.1.
| Arm | Type | Description |
|---|---|---|
| UPS, Liposarcoma or pleomorphic liposarcoma | EXPERIMENTAL | Undifferentiated Pleomorphic Sarcoma (UPS) or Liposarcoma (dedifferentiated or pleomorphic liposarcoma) Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion |
| Leiomyosarcoma | EXPERIMENTAL | Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion |
| Vascular Sarcoma Subtypes | EXPERIMENTAL | Including angiosarcoma and Epithelioid Hemangioendothelioma (EHE). Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion |
| Other | EXPERIMENTAL | Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion |
| Name | Type | Description |
|---|---|---|
| Epacadostat | DRUG | 100mg bid days 1-21 |
| Pembrolizumab | DRUG | 200mg/dose Day 1, Q 3 weeks |
Inclusion Criteria: * Male or female age ≥ 18 years at the time of informed consent * Be willing and able to provide written informed consent/assent for the trial * Be willing to comply with treatment protocol * Subjects must have a histologically confirmed metastatic and/or locally advanced sarcom...